Ipca Laboratories Limited today announced its unaudited financial results for the first quarter ended 30th June, 2012 of the financial year 2012-13.
Key Highlights of Q1 FY13
Net Total Income at Rs. 637.38 crores in Q1 FY13 as against Rs. 532.55 crores in Q1 FY12, growth of 20%.
Export Income at Rs. 366.73 crores in Q1 FY13 as against Rs. 296.66 crores in Q1 FY12, growth of 24%.
EBITDA at Rs. 141.78 crores in Q1 FY13 as against Rs. 94.26 crores in Q1 FY12, up by 50%.
EBITDA margin increased from 17.79% to 22.35%.
Net Profit at Rs. 42.98 crores in Q1 FY13 as against Rs. 61.67 crores in Q1 FY12, down by 30% on account of forex transactions / translations loss of Rs. 58.85 crores in the quarter as against forex transactions / translations gain of Rs. 9.10 crores in the corresponding quarter of the previous financial year.
Revenue Break-up
Formulations:
Total Revenue from formulations business at Rs. 448.69 crores in Q1 FY13 as against Rs. 395.55 crores in Q1 FY12, growth of 13%.
Revenue from Domestic branded formulations business at Rs. 224.18 crores in Q1 FY13 as against Rs. 188.97 crores in Q1 FY12, growth of 19%.
Revenue from export of formulations at Rs. 224.51 crores in Q1 FY13 as against Rs. 206.58 crores in Q1 FY12, growth of 9%.
Active Pharmaceutical Ingredients (APIs)
Total Revenues from Active Pharmaceutical Ingredients (APls) business at Rs. 181.56 crores in Q1 FY13 as against Rs. 130.78 crores in Q1 FY12, growth of 39%.
Revenues from Domestic Active Pharmaceutical Ingredients (APls) business at Rs. 39.34 crores in Q1 FY13 as against Rs. 40.70 crores in Q1 FY12, down by 3%.
Revenue from export of Active Pharmaceutical Ingredients (APls) at Rs. 142.22 crores in Q1 FY13 as against Rs. 90.08 crores in Q1 FY12, growth of 58%
Q1 FY13 at a glance (Rs. Crores)
|
1st Quarter ended
|
30.6.2012
|
30.6.2011
|
Growth
|
|
Net Total Income
|
637.38
|
532.55
|
20%
|
|
Export Income
|
366.73
|
296.66
|
24%
|
|
EBITDA
|
141.78
|
94.26
|
50%
|
|
Profit before Forex gain / loss and tax
|
115.33
|
74.09
|
56%
|
|
Forex (gain) / loss
|
58.85
|
(9.10)
|
-
|
|
Net Profit after Forex gain / loss and tax
|
42.98
|
61.67
|
(30%)
|
|
Earnings per share of Rs. 2/- each (Rs)
|
3.41
|
4.91
|
(30%)
|
About Ipca Laboratories:
Ipca Laboratories is a fast growing pharmaceutical major, with a strong thrust on exports. Exports to over 110 countries, now account for nearly 55% of Company's income. Ipca Laboratories is vertically integrated and produces finished dosage forms and Active Pharmaceutical Ingredients.